Emergent Biosolutions (NYSE:EBS) SVP Paul Anthony Williams Sells 3,000 Shares

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Trading Up 0.1%

NYSE:EBS opened at $8.29 on Friday. Emergent Biosolutions Inc. has a 12 month low of $5.61 and a 12 month high of $14.06. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. The firm’s 50 day moving average is $8.36 and its 200 day moving average is $9.65. The stock has a market capitalization of $427.51 million, a PE ratio of -29.59 and a beta of 2.34.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The business had revenue of $156.10 million during the quarter, compared to analyst estimates of $145.00 million.

Hedge Funds Weigh In On Emergent Biosolutions

Hedge funds have recently made changes to their positions in the stock. Palumbo Wealth Management LLC lifted its holdings in Emergent Biosolutions by 143.0% during the 4th quarter. Palumbo Wealth Management LLC now owns 117,121 shares of the biopharmaceutical company’s stock worth $1,448,000 after purchasing an additional 68,925 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in Emergent Biosolutions during the 3rd quarter valued at about $713,000. American Century Companies Inc. grew its holdings in Emergent Biosolutions by 3.9% during the 3rd quarter. American Century Companies Inc. now owns 2,382,378 shares of the biopharmaceutical company’s stock valued at $21,013,000 after buying an additional 90,216 shares in the last quarter. Ritholtz Wealth Management bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at about $1,346,000. Finally, Evolve Private Wealth LLC bought a new stake in shares of Emergent Biosolutions during the first quarter valued at about $546,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on EBS. Wall Street Zen lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright reduced their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Finally, UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.